Rebranding efforts include a new logo, overall brand presence, and corporate design.

Meeting to be held in London and Zurich on March 31-April 2 hosted by Cantor Fitzgerald.Light Up your Portfolio with Spark:Easily identify ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Neil Mcfarlane; President, Chief Executive Officer, Director; Zevra Therapeutics Inc Joshua Schafer; Chief Commercial Officer and Executive Vice President, Business Development; Zevra Therapeutics ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript March 11, 2025 Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.67 EPS, expectations were $-0.39.

Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call. Today's call is being recorded, and will be ...

and is comprised of serdexmethylphenidate (SDX), Zevra’s proprietary prodrug of d-methylphenidate (d-MPH) and is the sole active pharmaceutical ingredient of KP1077. KP1077 has been granted Orphan ...

Zevra Therapeutics Inc. (ZVRA) reported a net loss of $35.7 million for Q4 2024, equating to a loss of $0.67 per share, which was below analyst expectations of a $0.40 loss per share. The company ...

Zevra Therapeutics (ZVRA ... A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.44 per share when it actually produced a loss of $0.69, delivering ...